MX384246B - POLIPÉPTIDO DE UNIÓN A TCR ALFA BETA PARA USARSE EN LA DISMINUCIÓN DE LINFOCITOS TAß. - Google Patents

POLIPÉPTIDO DE UNIÓN A TCR ALFA BETA PARA USARSE EN LA DISMINUCIÓN DE LINFOCITOS TAß.

Info

Publication number
MX384246B
MX384246B MX2016005687A MX2016005687A MX384246B MX 384246 B MX384246 B MX 384246B MX 2016005687 A MX2016005687 A MX 2016005687A MX 2016005687 A MX2016005687 A MX 2016005687A MX 384246 B MX384246 B MX 384246B
Authority
MX
Mexico
Prior art keywords
methods
binding polypeptide
immunosuppressive therapy
humanized
alpha beta
Prior art date
Application number
MX2016005687A
Other languages
English (en)
Other versions
MX2016005687A (es
Inventor
Andreas Menrad
Daniel Snell
Gina Lacorcia
Gregor Blank
Karin Schilbach
Rupert Handgretinger
Original Assignee
Genzyme Corp
Univ Eberhard Karls Tuebingen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp, Univ Eberhard Karls Tuebingen filed Critical Genzyme Corp
Publication of MX2016005687A publication Critical patent/MX2016005687A/es
Publication of MX384246B publication Critical patent/MX384246B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a métodos mejorados para uso de un polipéptido de unión humanizado específico para el receptor de linfocitos T alfa beta (aß-TCR). En particular, esta descripción está relacionada con métodos mejorados de uso de un anticuerpo anti-aß-TCR humanizado, que deriva del anticuerpo monoclonal murino BMA031, en terapia inmunosupresora. También se proporcionan métodos nuevos usando anticuerpos monoclonales humanizados y/o fragmentos de anticuerpo monoclonal humanizado (por ejemplo, anticuerpos anti-aßTCR y/o fragmentos de los mismos). Se proporcionan métodos nuevos que usan administración repetida de anticuerpos monoclonales humanizados y/o fragmentos de anticuerpos monoclonales humanizados (por ejemplo, anticuerpos anti-aßTCR y/o fragmentos de los mismos) para reducir linfocitos T aß en el sujeto en relación con linfocitos T yd en el sujeto.
MX2016005687A 2013-10-30 2014-10-30 POLIPÉPTIDO DE UNIÓN A TCR ALFA BETA PARA USARSE EN LA DISMINUCIÓN DE LINFOCITOS TAß. MX384246B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361897809P 2013-10-30 2013-10-30
PCT/US2014/063254 WO2015066379A2 (en) 2013-10-30 2014-10-30 Methods for enhancing immunosuppressive therapy by multiple administration of alpha beta tcr-binding polypeptide

Publications (2)

Publication Number Publication Date
MX2016005687A MX2016005687A (es) 2017-03-30
MX384246B true MX384246B (es) 2025-03-14

Family

ID=52021413

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016005687A MX384246B (es) 2013-10-30 2014-10-30 POLIPÉPTIDO DE UNIÓN A TCR ALFA BETA PARA USARSE EN LA DISMINUCIÓN DE LINFOCITOS TAß.

Country Status (8)

Country Link
US (2) US11142575B2 (es)
EP (1) EP3063174B1 (es)
CN (1) CN106795220A (es)
AU (2) AU2014342182B2 (es)
CA (1) CA2928756A1 (es)
MX (1) MX384246B (es)
SG (2) SG11201603193PA (es)
WO (1) WO2015066379A2 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY34317A (es) 2011-09-12 2013-02-28 Genzyme Corp Anticuerpo antireceptor de célula T (alfa)/ß
CN106795220A (zh) * 2013-10-30 2017-05-31 建新公司 通过αβTCR结合多肽的多重施用的用于增强免疫抑制疗法的方法
WO2016059220A1 (en) 2014-10-16 2016-04-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Tcr-activating agents for use in the treatment of t-all
WO2017049159A1 (en) * 2015-09-16 2017-03-23 Ledebur Jr Harry C T-CELL RECEPTOR (TCR) TARGETING THERAPIES FOR IMMUNE-MEDIATED ADVERSE DRUG REACTIONS (ADRs) AND OTHER CONDITIONS
CN108070644B (zh) * 2016-11-08 2021-06-29 国家卫生计生委科学技术研究所 一种妊娠高血压的诊断系统
TW201829463A (zh) 2016-11-18 2018-08-16 瑞士商赫孚孟拉羅股份公司 抗hla-g抗體及其用途
US20200157172A1 (en) * 2017-07-07 2020-05-21 HANMl PHARM. CO., LTD. Novel therapeutic enzyme fusion protein and use thereof
CN109777778B (zh) * 2017-11-14 2023-07-18 中国科学院广州生物医药与健康研究院 一种基因改造的γδT细胞
DE102017127984B4 (de) * 2017-11-27 2019-12-05 Immatics US, Inc. Verfahren für die Vermehrung und Aktivierung von γδ-T-Zellen
US12247060B2 (en) 2018-01-09 2025-03-11 Marengo Therapeutics, Inc. Calreticulin binding constructs and engineered T cells for the treatment of diseases
EP3765517A1 (en) 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
AR114789A1 (es) 2018-04-18 2020-10-14 Hoffmann La Roche Anticuerpos anti-hla-g y uso de los mismos
WO2020010250A2 (en) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
AU2020226893B2 (en) 2019-02-21 2025-02-27 Marengo Therapeutics, Inc. Multifunctional molecules that bind to T cell related cancer cells and uses thereof
JP7579795B2 (ja) 2019-02-21 2024-11-08 マレンゴ・セラピューティクス，インコーポレーテッド ＮＫｐ３０に結合する抗体分子およびその使用
JP7575401B2 (ja) * 2019-04-03 2024-10-29 ジェンザイム・コーポレーション 断片化が低減した抗アルファベータｔｃｒ結合ポリペプチド
CN115003698A (zh) * 2019-11-14 2022-09-02 马伦戈治疗公司 抗tcr抗体分子及其用途
WO2021138474A2 (en) * 2020-01-03 2021-07-08 Marengo Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
WO2022129120A1 (en) 2020-12-17 2022-06-23 F. Hoffmann-La Roche Ag Anti-hla-g antibodies and use thereof
KR20240004937A (ko) 2021-05-05 2024-01-11 이매틱스 바이오테크놀로지스 게엠베하 Bma031 항원 결합 폴리펩타이드
WO2023025668A1 (en) 2021-08-25 2023-03-02 Asociación Centro De Investigación Cooperativa En Biociencias-Cic Biogune Methods for the generation of stem cell memory t cells for adoptive t cell therapy
CN118108842B (zh) * 2023-06-09 2026-06-05 浙江大学 人源化抗cd24抗体及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2018248A1 (en) * 1989-06-07 1990-12-07 Clyde W. Shearman Monoclonal antibodies against the human alpha/beta t-cell receptor, their production and use
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US20050058641A1 (en) 2002-05-22 2005-03-17 Siemionow Maria Z. Tolerance induction and maintenance in hematopoietic stem cell allografts
JP2007512846A (ja) 2003-12-04 2007-05-24 ゼンコー・インコーポレイテッド 増加した宿主ストリング含有量を有する変異体タンパク質の生成方法およびその組成物
JP5238936B2 (ja) 2005-03-25 2013-07-17 ジーアイティーアール，インク． Ｇｉｔｒ結合分子およびその使用
WO2008094176A2 (en) 2006-06-19 2008-08-07 Tolerx, Inc. Ilt3 binding molecules and uses therefor
GEP20125693B (en) 2007-01-09 2012-11-26 Biogen Idec Inc Sp35 antibodies and usage thereof
CA2735193A1 (en) 2008-08-26 2010-03-11 Macrogenics, Inc. T-cell receptor antibodies and methods of use thereof
DK2542256T3 (da) 2010-03-04 2019-08-26 Macrogenics Inc Antistoffer reagerende med b7-h3, immunologisk aktive fragmenter deraf og anvendelser deraf
US9018006B2 (en) * 2010-07-23 2015-04-28 The University Of Toledo Stable Tregs and related materials and methods
UY34317A (es) * 2011-09-12 2013-02-28 Genzyme Corp Anticuerpo antireceptor de célula T (alfa)/ß
CN106795220A (zh) * 2013-10-30 2017-05-31 建新公司 通过αβTCR结合多肽的多重施用的用于增强免疫抑制疗法的方法

Also Published As

Publication number Publication date
US20160244523A1 (en) 2016-08-25
AU2014342182A1 (en) 2016-05-19
SG10201803473WA (en) 2018-06-28
AU2014342182B2 (en) 2020-05-14
WO2015066379A3 (en) 2015-07-09
CN106795220A (zh) 2017-05-31
EP3063174A2 (en) 2016-09-07
MX2016005687A (es) 2017-03-30
US20220098299A1 (en) 2022-03-31
CA2928756A1 (en) 2015-05-07
EP3063174B1 (en) 2020-12-09
US11142575B2 (en) 2021-10-12
SG11201603193PA (en) 2016-05-30
WO2015066379A2 (en) 2015-05-07
AU2020217395A1 (en) 2020-09-03

Similar Documents

Publication Publication Date Title
SG10201803473WA (en) Methods for enhancing immunosuppressive therapy by multiple administration of alpha beta tcr-binding polypeptide
PH12020500368A1 (en) B7-h4 antibodies and methods of use thereof
WO2014011988A3 (en) Enhancing activity of car t cells by co-introducing a bispecific antibody
PH12020500677A1 (en) Neoantigens and uses thereof
MY190711A (en) Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
CR20200014A (es) Molécula de polipéptido con especificidad dual mejorada
MX2020003046A (es) Anticuerpos anti-hla-a2 y metodos para utilizar los mismos.
AU2014236098A8 (en) Treatment of cancer using humanized anti-CD19 chimeric antigen receptor
PH12017500268A1 (en) Antibodies and chimeric antigen receptors specific for cd19
TN2013000076A1 (en) Anti-ox40 antibodies and methods of using the same
EP3593812A3 (en) Treatment of cancer using chimeric antigen receptor
MX357193B (es) Moleculas de union anti-alfa sinucleina.
NZ628314A (en) Cd47 antibodies and methods of use thereof
HK1207655A1 (en) Affinity matured anti-ccr4 humanized monoclonal antibodies and methods of use
MX2015014017A (es) Variante de la region fc.
MX2013005015A (es) Anticuerpos anti-il-23.
MX2015003150A (es) Anticuerpos específicos de polipeptido amiloide de islote humano (hiapp) y sus usos.
PL422231A1 (pl) Komórki immunologiczne CAR do leczenia nowotworów
MX2018016121A (es) Preparacion de anticuerpos monoclonales marcados con 212pb.
WO2019112347A3 (ko) 악성 b 세포를 특이적으로 인지하는 항체 또는 그의 항원 결합 단편, 이를 포함하는 키메라 항원 수용체 및 이의 용도
NZ629553A (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
MX2016001383A (es) Metodos para reducir la tasa de exacerbacion de asma mediante el uso de benralizumab.
MY187971A (en) Antibody constructs for cd70 and cd3
WO2012106669A3 (en) Foxc1 antibodies and methods of their use
HK1227898A1 (en) Methods for enhancing immunosuppressive therapy by multiple administration of alpha beta tcr-binding polypeptide